Dexmedetomidine combined with midazolam for sedation in children with autism

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500096289

Enrollment

Unknown

Registered

2025-01-21

Start date

2025-03-04

Completion date

Unknown

Last updated

2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sedation of autistic children

Interventions

A groups:55 = DQ = 75 indicates mild developmental delay, dexmedetomidine combined with midazolam

B groups:40 = DQ = 54 indicates moderate developmental delay, dexmedetomidine combined with midazolam

C groups:25 = DQ = 39 severe developmental delay, dexmedetomidine combined with midazolam

Eligibility

Sex/Gender

All

Age

1 Years to 6 Years

Inclusion criteria

Inclusion criteria: Brain MRI was performed on children with autism, regardless of gender, aged 1 to 6 years,ASA?-II

Exclusion criteria

Exclusion criteria: ASA > ?, nasal mucosa, oral mucosa injury; Severe respiratory infection; History of allergy to sedative and anesthetic drugs.

Design outcomes

Primary

Measure	Time frame
Ramsay score;	—

Countries

China

Contacts

Public ContactLIXIA PAN

Guangxi maternal and Child Health Hospital

115861353@qq.com+86 182 7714 7759

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026